Genworth Financial is maintained as a Buy, but with increased caution due to persistent challenges outside its Enact Holdings stake. GNW's valuation remains heavily discounted relative to its $4.7B ACT stake, while legacy long-term care and closed-block businesses continue to drag earnings. Shareholder value is driven by aggressive buybacks, with FY 2026 repurchases guided to $195–$225M and a potential $750M legal windfall pending appeal.